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Abstract
Nanotechnology currently plays a pivotal role in several fields and has enabled substan-
tial advances in a relatively short time. In biomedicine, nanomaterials can be potentially 
employed as a tool for early diagnosis and an innovative mode of drug delivery. Novel 
nanomaterials are currently widely manipulated without a full assessment of their poten-
tial health risks. It is commonly thought that nanomaterials’ first contact with the organism 
is through the different components of the immune system. However, if the entry route is 
intravenous, the first contact will be with the blood’s components (erythrocytes, platelets, 
white cells, plasma and complement proteins). The presence of nanomaterials within a 
dynamic environment such as the bloodstream can produce potential harmful effects fol-
lowing interaction with several blood components. The design of innovative strategies 
leading to the development of more hemocompatible nanomaterials is also necessary.
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1. Introduction
Current nanotechnology plays a pivotal role in a variety of fields and has enabled substan-
tial advances in a relatively short time. In biomedicine, nanomaterials can be potentially 
employed as a tool for early diagnosis and an innovative mode of drug delivery [1–3]. As 
nanomaterial research grows, increased occupational exposure and very likely environmental 
pollution occur due to a lack of handling regulations.
© 2018 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The studies about the nanomaterials  started fifteen years ago, and knowledge regarding their 
toxic potential is still limited and without appropriate regulatory measures in place [4–6]. 
Toxicologists, epidemiologists, and sociologists have particularly debated the future implica-
tions of nanotechnology as well as concerns regarding their toxicity and potential environ-
mental impact. Nanomaterial application has expanded across a variety of fields, and the lack 
of attention involving their regulation is worrisome [7]. Novel nanomaterials are currently 
widely manipulated without a full assessment of their potential health risks, while nano-
materials that are already commercially available have no Safety Data Sheets. There is an 
urgent need for studies that will help identify, understand, and predict the cellular or tissue 
responses that nanomaterials can trigger in humans: it is important to understand how safe 
they are and establish respective protective measures.
The potential medical applications of nanomaterials are spreading to the fields of imaging, 
therapy, and nanodiagnostics [8, 9]. Regardless of the medical use they are given, nano-
materials come into contact with human tissues and cells which can trigger reactions that 
might include nanomaterial-blood interactions, damage, acute inflammation, and chronic 
inflammation.
Human beings have developed evolutionary defense mechanisms against the microorgan-
isms and foreign particles with which they might potentially interact. When effective, these 
mechanisms provide immunity, that is, resistance to the invasive agents. Their failure results 
in illness. The human immune system modulates many important biological protective pro-
cesses [10–12]. It coordinates responses involving a variety of cells and molecules to protect 
us from invading pathogens, as well as cancer cells and foreign agents [13, 14]. It is commonly 
thought that nanomaterials’ first contact with the organism is via the different components of 
the immune system. However, if the entry route is intravenous, the first contact will be with 
the blood’s components (erythrocytes, platelets, white cells, plasma and complement pro-
teins). This interaction can lead to different associated pathophysiological processes, as will 
be enunciated below (Figure 1). Knowing what happens when nanomaterials interact with 
blood components is an essential step when evaluating health risks.
Until now, all biomaterials meant for use in humans trigger a tissue response when they come in 
contact with either healthy or sick tissue [15–17]. However, this response is triggered by physical 
contact between the tissue and the biomaterial which is implanted in an organ or tissue. When 
we talk about nanomaterials, it should be considered that due to their size, effects will take place 
at a nanolevel, that is, at the cellular or molecular levels. The response they trigger will not be 
necessarily the same as the one occurring after the implantation of a biomaterial. Additionally, 
since the projected applications of nanomaterials in nanomedicine involve diagnosis (imaging) 
and treatment (nanotransporters)—mostly for cancer—host contact with nanomaterials will be 
of an intravascular nature. Nanomaterial-blood interactions have been linked to inflammatory 
responses; early response to this damage mainly involves the blood and the vascular endothe-
lium. Once nanomaterials enter the bloodstream, they come into contact with blood cells (red 
cells, white cells, and platelets), complement proteins, and plasma proteins. It is important to 
understand how they interact with those elements to assess their effective toxic potential, in 
both the blood and remote sites.
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1.1. Interaction of nanomaterials with red cells
Erythrocytes or red blood cells are exposed to attacks throughout their life span which results 
in constant biochemical and morphological changes. These cells’ contact with nonbiological 
objects may significantly affect their functions [18, 19]. Nanomaterial interaction with these 
cells has different effects depending on their intrinsic characteristics. Venkatesan et al. [20] and 
Choimet et al. [21] recently reported the high hemocompatibility of chitosan  nanoparticles 
loaded with siRNA-Npr3 and nanoparticles formed with colloidal apatite; however, chitosan 
nanoparticles dissolved with tripolyphosphate (TPP) to acid pH produce hemolysis [22]. Kim 
et al. [23] carried out rheological measurements and showed that, at concentrations of 12.5 
μg/mL, silica nanomaterials caused hemolysis, deformation, and aggregation of erythrocytes. 
It is well known that negatively charged silver nanoagents (AgNPs) strongly interact with 
organic cations of the erythrocyte membrane and stimulate hemolysis [24]. Wang et al. [25] 
found that red blood cells and hemoglobin concentrations increased in rats treated with gra-
phene quantum dots (5 mg/kg). The reason why erythrocytes do not show immediate dam-
age when exposed to toxic substances is because they have a system of antioxidant defense 
that includes nonenzymatic antioxidants such as glutathione and antioxidant enzymes such 
Figure 1. Interaction of nanoparticles (NPs) with bloodstream components and physiological effects.
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as catalase and peroxiredoxin-2 [26, 27]. The presence of this defense system could explain 
their resistance to the damage induced by nanoparticles, indicating that these cells are not as 
sensitive to the toxic effects of nanoparticles. However, one of the factors that can influence 
whether a nanoparticle leads to hemolysis or not is the presence of surfactants [28] and [29] 
coatings. Surfactants confer different properties to nanomaterials, altering charge, interfacial 
tension, and becoming an amphiphilic molecule, which reduces the nanomaterial coales-
cence. Coatings add different chemical groups to the surface of nanoparticles confer different 
chemical behaviors. However, hemocompatibility will be different for each type of nanopar-
ticle, making it impossible to anticipate if one nanoparticle will be toxic when surfactants or 
coatings are added.
Recent studies have shown the usefulness of erythrocytes as nanoparticle carriers: they 
assist their adherence to the vascular endothelium [30] and serve as a platform to bypass 
the immune system [31, 32]. The physical and chemical properties of erythrocytes are ideal 
for drug delivery. According to data regarding cell-based therapies, those using erythrocytes 
have proved to be the most stable, versatile, safe, and easy to manufacture. This strategy 
is based on temporarily opening pores in the membrane of erythrocytes, easily transport-
ing drugs and ensuring that the latter can stay within these cells once the pores have closed 
[33]. One of the main uses for this system is the delivery of contrast agents contained within 
superparamagnetic iron oxide (SPIO) nanoparticles, ultrasmall superparamagnetic iron oxide 
(USPIO) nanoparticles, very small superparamagnetic iron oxide (VSPIO) nanoparticles, and 
monocrystalline iron oxide nanocompound (MION) particles, which are already registered 
and approved for use in the United States and Europe [34]. These have been successfully 
employed for magnetic particle inspection (MPI) techniques involving the imaging of vessels 
or structures filled with blood, both during interventions and when monitoring long-term 
cardiovascular diseases [35]. There is no doubt regarding the hemolytic potential of nanoma-
terials, and since the presence of hemolysis for long periods can have fatal health effects, an 
assessment of each nanomaterial’s hemolytic potential is quite important.
1.2. Interaction of nanomaterials with platelets
As they go through the blood, nanoparticles can also interact with platelets. When these blood 
cells come into contact with any material, they adhere to its surface and begin a cascade of sig-
nals that eventually leads to fibrin cross-linking and clot formation. While platelet binding is 
the main process that maintains hemostasis and prevents hemorrhages, it can also lead to the 
appearance of potentially deadly thrombi that can cause strokes or cerebrovascular accidents 
[36]. Thrombus formation involves a series of cellular events that entail the participation of 
molecular components, mainly proteins. If a nanomaterial has the capacity to induce platelet 
aggregation and alter the normal process of coagulation, it could lead to bleeding or throm-
bosis. Hence,  it is important to know the thrombogenic capacity of each type of nanomaterial, 
especially when considering their potential nanobiomedical applications.
There are few reports regarding the interaction between nanoparticles and platelets. Unfor-
tunately, most of them show evidence of the procoagulant effects of employed nanomaterials, 
along with their potential health risks if the exposed person is going through pathological 
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processes such as cardiovascular disease or metabolic syndrome. Nanoparticle-platelet inter-
action and endothelial injury may result in the activation of the coagulation cascade, the for-
mation of blood clots, and the partial or total occlusion of blood vessels by thrombi. These 
effects will depend not only on the size, charge, hydrophobicity, or type of cover but also on 
the intrinsic characteristics of the nanoparticles (Figure 2).
Nanoparticle size seems to be an important factor for platelet activation. It has been observed 
that the smaller the nanoparticles are, the more likely it is that these cells will be activated. 
It was already demonstrated that platelet response increases with the size reduction of gold 
nanoparticles (AuNPs) [37]. On the other hand, SiO
2
 nanoparticles have been shown to 
produce more severe effects when they are about 50–70 nm in size. Concordantly, another 
work suggests that the effect of 200 nm SiO
2
 particles was more intense than that caused 
by 50 nm ones [38]. Nanoparticles’ capacity to induce platelet activation has been amply 
reported. Examples include gold (AuNP) and silver (AgNP) nanoparticles, as well as CdTe 
and CdSe quantum dots [39–41]. As far as coating is concerned, carboxyl, amino, phosphate, 
or hydroxyls are all known to lead to platelet activation [42]. On the other hand, negatively 
charged surfaces can more easily initiate thrombotic events because, in physiological coagu-
lation, platelet contact with anionic surface starts the coagulation cascade [43]. It was recently 
reported that, at low concentrations (50 ng/mL), TiO
2
 nanoparticles could trigger the activa-
tion of the contact system, leading to inflammation-induced thrombosis in a complete blood 
in vitro model [44].
Figure 2. Effect of nanoparticles properties on human physiological response.
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Simple and multiwalled carbon nanotubes (SWCNTs and MWCNTs), iron nanoparticles (Fe
2
O
3
 
and Fe
3
O
4
NPs), silicon oxide nanoparticles (SiO
2
 NPs), pegylated nanoparticles (PEGylated), 
titanium oxide nanoparticles (TiO
2
NPs), and zinc oxide nanoparticles (ZnONP) are known 
not to induce platelet activation [45]. This makes them ideal for theranostics. Interestingly, 
just like several types of nanoparticles that can induce platelet activation, certain nanomate-
rials are being used for diagnosis in thrombotic disease since thrombogenic proteins range 
from nanometers to micrometers in size. High-resolution imaging is required to observe these 
proteins in real time, and this is being achieved via the use of nanotransporters. For example, 
liposomes contain thrombin inhibitors for acute thrombosis, perfluorocarbon nanoparticles 
with thrombin inhibitors, polymer nanotransporters with antithrombotic activity, magnetic 
nanoparticles conjugated with thrombolytic activity urokinase, and Fe
2
O
3
 nanoparticles 
conjugated with plasminogen activator for thrombosis [46]. Identifying the prothrombotic 
or nanotransporting potential of a nanomaterial is important given its potential medical 
implications.
1.3. Interaction of nanomaterials with peripheral mononuclear cells
Peripheral blood mononuclear cells (PBMC) are another important element in the blood-
stream. While there are many studies on lymphocyte cell lines, the use of PBMC cells allows 
for the simultaneous analysis of nanoparticle effects on several important immune cells such 
as B-cells, T-cells, monocytes, and natural killer (NK) cells. Studying nanomaterials with 
these types of cells are crucial since these will interact with nanoparticles once the latter are 
introduced into the blood torrent. The peripheral blood mononuclear cells (lymphocytes and 
monocytes) represent a host defense system that is capable of releasing various inflammatory 
mediators after its activation. The physicochemical properties of nanomaterials can act as 
intrinsic signals that aid immunity.
Immune cells need to communicate to exercise their function. One way is via the production 
and release of exosomes, nanovesicles that are naturally present in and are released by the 
majority of cells in the body. These exosomes can act as a means of communication for trans-
ferring functional proteins, mRNA and microRNA. Studies conducted by Andersson-Willman 
et al. [47] show that in subtoxic concentrations, TiO
2
 and ZnO nanoparticles do not interfere 
with the traffic and release of these exosomes in PBMC cell populations. Adhesion molecules 
such as integrins and selectins also play an important role in immune response. ZnO NPs 
alter the expression of several integrins, L-selectin and chemokine receptor CXCR4, impor-
tant molecules for key cellular functions such as adhesion, migration, and cell  proliferation 
[48]. Immune cells also have other functions, such as inducing the proliferation of other cells, 
phagocytizing, or killing. It has been pointed out that peripheral blood immune cells (lym-
phocytes, NK cells, granulocytes, and monocytes) have a different sensitivity to the effect of 
polylactic-glycolic acid (PLGA-PEO) nanoparticles. These particles suppressed the prolifera-
tive function of lymphocytes and the killing activity of NK cells, but stimulated phagocytic 
activity of granulocytes and monocytes, as well as the respiratory burst of phagocytes [49].
Nanoparticles have different toxic effects in human PBMC. Lankoff et al. [50] used silica 
nanoparticles and observed no significant cytotoxic and genotoxic effects in peripheral blood 
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lymphocytes. However, cell proliferation was affected in a concentration-dependent manner. 
Those same authors found that surface charge and zeta potential are important for the bind-
ing and uptake of nanoparticles into cells. Peripheral blood lymphocytes died after exposure 
to nanoparticles containing silicon and carbon nanotubes, an effect that was dependent on the 
concentration of the nanoparticles employed [51, 52]. TiO
2
, ZrO
2
, and Al
2
O
3
 nanoparticles did 
not damage these cells’ DNA at concentrations of 1, 10, and 100 μg/mL [53]. Nanoparticle size 
seems to influence toxicity. Studies involving peripheral blood lymphocytes treated with SiO
2
 
nanoparticles of different sizes (6, 20, and 50 nm) induced size-dependent cytotoxic, geno-
toxic, and mutagenic effects [54].
Nanoparticle coating also seems to influence the toxicity induced in peripheral blood mono-
nuclear cells. Oleate F
3
O
4
 nanoparticles produce cytotoxic and genotoxic effects. Oleate seems 
to confer a different load and agglomeration potential, favoring cell uptake and, therefore, 
cytotoxicity [55]. Recently, Farace et al. studied the effect of nanocapsules (PCs, 170–300 nm) 
coated with chitosan and pluronic PEG on peripheral blood mononuclear cells and subpopu-
lations of T lymphocytes and monocytes which were taken as representative of the innate 
immune response [56]. They observed that different types of NCs produce different effects 
on immune cells. For example, the PEG NCs were completely inert, while Pluro NCs and 
Chito NCs had immunomodulatory effects. Pluro nanoparticles induced an immune response 
through CD69 up-modulation in monocytes and increased the release of IL-6, IL-10, IL-12, 
and TNFα. On the other hand, Chito nanoparticles produced apoptosis in monocytes and 
T-cells, as an increase in the secretion of pro-inflammatory cytokines (TNFα and IL-12) [57]. 
Interestingly, Chito NCs induced the secretion of IL-4 and IL-13 cytokines. Normally, the T 
effector (Th
2
) helper cells produce a cytokine profile that includes IL-4, IL-6, IL-10, and IL-13. 
These cytokines signal B-cells to proliferate and differentiate in antibody-producing plasma 
cells. The possible activation of Th
2
 cells mediated by Chito NCs might be responsible for the 
induction of allergy in humans.
1.4. Interaction of nanomaterials with complement proteins
The complement system is part of innate immunity and is one of the oldest defense systems. 
Any absence or abnormalities in this system or any of its components can cause serious and 
even deadly disease. The complement system has three known modes of activation: the clas-
sical, alternative, and lectin pathways, which differ both in their activation mechanisms and 
initial components. The main biological functions of this system include (a) opsonization, (b) 
chemotaxis, (c) cellular and bacterial lysis, (d) anaphylatoxin function, and (e) participation 
in the elimination of immune complexes [58]. The system is composed of several components 
(C1, C2 to C9) and factors (B, D, HI, and P) and gets its name from the fact that it complements 
the immune response mediated by antibodies [59].
It is not known why certain nanoparticles cause the activation of the complement system, 
but it is of knowledge that the surface charge plays an important role. It has been noted that 
charged nanoparticles do more to activate the complement than neutral counterparts (e.g., 
polypropylene sulfur nanoparticles, lipid nanocapsules, polycation-based nanoparticles con-
taining cyclodextrin and polystyrene nanospheres [60–63]). Also, polymer coatings made of 
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polyethylene glycol (PEG) and poloxamine-908 partially neutralize the surface charge and 
reduce the activation of the complement system [64, 65]. However, similar studies using dex-
tran and chitosan showed that the size and shape of the polymer influenced the degree of 
complement activation, which was not determined by the effects of the load [66]. The pres-
ence of thiol groups in the nanoparticle’s surface also increases the activation of the comple-
ment [67].
We know that hydrophobic surfaces are more powerful activators than hydrophilic ones and 
that the inclusion of NH
2
, –OH, or –COOH groups influences the activation of the comple-
ment [68]. Nanotubes functionalized with psychosine activate the complement via the clas-
sical pathway [69]. Several studies have shown that the activation of the complement can be 
dependent on size, polydispersity index, zeta potential, and surface ligand density [70–72].
The activation of the complement system leads to an inflammatory response via the release of 
anaphylatoxins (e.g., C3a and C5a), C3b and C5b–C9 lytic complex, since this response origi-
nates uncontrolled activation, which can lead to organism collapse [73]. One of the diseases 
that has been directly associated to the activation of the complement system is C activation-
related pseudoallergy (CARPA), which entails reactions of hypersensitivity. Such situations 
demand security evaluations and the development of technologies that consider complement 
activation and nanomaterials’ potential to induce CARPA [74]. Complement activation has 
also been associated with the development and growth of tumors [75]. The generation of C5a 
in a tumor environment increases tumor growth by promoting the recruitment of suppres-
sor cells derived from myeloid in malignant tumors and the deregulation or suppression of 
CD8 cytotoxic cells. This is therefore another important consideration when evaluating new 
nanomaterials.
It is clear that nanomaterials can have different effects on the components of the immune sys-
tem in peripheral blood and at the tissue level. It is also evident that the physical, chemical, 
and optical properties of nanomaterials are critical for this interaction. That is in fact what has 
led to the design of tools that can be employed in the field of immunology. Nanomaterials are 
being used in the development of vaccines and immunotherapy and even therapeutic meth-
ods that seek to inhibit the complement system in cancer treatment [76]. There is an urgent 
need to understand the exact mechanisms of nanoparticle/immune interaction so as to have a 
more complete picture of what could actually happen in humans, thus ensuring more effec-
tive and secure applications.
1.5. Interaction of nanomaterials with plasma proteins
So far, there is no evidence that just by entering the bloodstream, nanoparticles can interact 
with associated cells and molecules and trigger a variety of potentially adverse effects. As 
nanoparticles go through the systemic circulation, they will also interact with plasma pro-
teins. Protein adsorption in biological medium is an important issue when measuring biologi-
cal response to nanoparticles [77–79]. Binding of plasma components and the formation of 
nanoparticle-protein interactions largely determines nanoparticle fate in the systemic circula-
tion and should influence functionality as much as the plasma protein binding of drugs [80]. 
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Knowledge regarding nanoparticle-protein interaction mechanisms has evolved over the past 
few years. Initially, several authors had indicated that protein adsorption decreased subse-
quent to the functionalization of the nanomaterial since the hydrophobicity of the nanoparti-
cle’s surface was also reduced [81]. However, nanoparticle-protein interaction is very complex 
and that the scenario will depend on whether this interaction occurs in the blood, interstitial 
liquid, or some other biological liquid, as well as the specific surface properties of particular 
nanoparticles (size, shape, load, composition, and surface functionalization) [82].
It has been recently noted that once a nanoparticle enters the biological environment, it 
becomes coated in proteins, the so-called protein corona that will influence the fate of the 
nanoparticle inside the organism (i.e., the time spent in the bloodstream, biodistribution, cel-
lular uptake, and intracellular localization) (Figure 3). This will also depend on the biological 
environment and on whether the biological environment is physiologically ill or healthy [83]. 
In addition to the above, it must be considered that the ultimate goal in nanomedicine is to 
Figure 3. Nanoparticles (NPs) in bloodstream and corona protein formation.
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use nanoparticles as transporters or a contrast medium for imaging. For theranostic purposes, 
nanoparticles must be functionalized with peptides, proteins, antibodies, oligonucleotides, or 
drugs, which means that the proteins that make up the corona will probably vary depending 
on the molecule with which the nanoparticle is conjugated and will provide the nanomate-
rial not only with a new biological identity but also with new physicochemical properties, 
changing shape, size, load, surface composition, and state of aggregation. This will also allow 
conformational changes [84, 85].
The binding of nanoparticles to plasma proteins such as albumin can increase biological prop-
erties that reduce the activation of the complement system, increasing blood circulation time 
and reducing toxicity [86]. In this regard, it would seem that the adsorption of circulating pro-
teins might confer safety, facilitate interactions mediated by receptors, and improve the phar-
macokinetic profile, i.e., these are potential theranostic advantages. However, the proteins 
that are involved in relevant physiological and toxicological processes in the bloodstream, 
such as the complement and coagulation factors, have also been identified forming the pro-
tein corona. The formation of the latter may additionally reduce target cellular interactions by 
making the ligands inaccessible to their surfaces [87]. For these reasons, the formation of the 
protein corona could be disadvantageous for theranostic purposes.
Another subject of study in this regard is that of the “hard or soft corona.” The term “hard 
corona” describes a long life and low complexity balance, while “soft corona” consists of the 
formation of layers of highly complex biomolecules that exchange quickly. That said, this 
concept is not widely used by researchers, and studies on ligand-receptor interaction with 
nanoparticles do not specify if the interaction is with a hard or soft corona [88].
When does the protein corona form and how quickly? Studies by Tenzer et al. [89] showed 
almost instant formation upon nanoparticle contact with the blood (<30 s). This group studied 
positively and negatively charged polystyrene nanoparticles (nPsNPs and pPsNPS, respec-
tively) and silica nanoparticles of various sizes (Ø ≈ 35, 120, and 140 nm), loads, and surface 
modifications (unmodified amine and carboxylate), exposing them to human plasma for dif-
ferent periods of time. They quantified the formation of 166 different protein coronas every 
30 s for PsNPs and silica nanoparticles (35 nm). When modified the surfaces were able to 
quantify the formation of 300 different protein coronas.
Some authors have pointed out that the protein corona can increase the useful drug load 
capacity of nanoparticles. The very small size of the nanoparticles facilitates their travel 
down the bloodstream, their incorporation into cells, and their interaction with the cellular 
compartments with different molecules, including DNA. A way in which the protein corona 
can improve not only nanoparticles’ drug transporting capacities but also their pharmacoki-
netic properties is by increasing payload capability through the use of porous materials (e.g., 
porous silicon) that can be packaged with the drug, as well as through the volume increase 
of liposomes. However, most current methods, unaware of the formation of the protein 
corona, typically load the drugs over the nanoparticles surface via chemical conjugation or 
adsorption. In these cases, the maximum amount that can be charged is restricted to a single 
layer [90]. Nanoparticles functionalized with polyethylene glycol (PEG) have been recently 
Unraveling the Safety Profile of Nanoscale Particles and Materials - From Biomedical to Environmental Applications46
 developed. PEG provides colloidal stability even under conditions of physiological salinity 
caused by interparticle repulsion. However, even complex pegylation is unable to completely 
prevent the formation of the protein corona, even though the degree of protein adsorption is 
clearly reduced [91].
The adsorption of serum proteins and the formation of a corona are part of the immune 
response. Expanding the circulation time of the nanoparticles means more contact with the 
blood proteins, a higher probability of thrombogenicity, and the activation of the complement 
system [92]. Since the corona depends on the characteristics of the nanoparticle (chemical 
surface, size, shape, and charge), these properties could be adjusted in such a way for the 
proteins that make it up to mitigate the immune response. Tuning the properties of affinity 
toward the corona could optimize the biocompatibility of the nanoparticles and reduce their 
toxicity. However, this process is not easy, and few researchers designing nanomaterials take 
corona formation into consideration. Ideally, nanoparticle development should encompass 
studies that provide data regarding nanoparticle-protein interactions, as is customary during 
the development of a new drug. There are few reports on this subject, and limited knowledge 
in this field may be a reason for the lack of successful clinical treatments.
1.6. Interaction of nanomaterials with the vascular endothelium
Oftentimes, the study of nanomaterial-blood interactions focuses on blood cells and proteins. 
However, the vascular endothelium where these elements are contained must also be taken 
into consideration and plays an important role because these cells and proteins interact with 
it triggering severe pathophysiological processes. In addition to the multiple direct physical 
interactions between nanoparticles and endothelial cells, nanoparticles enter and circulate in 
the blood vessel. Among other important functions, the endothelium maintains the vascular 
tone, vascular cell growth regulation, leukocyte and platelet adhesion regulation, thrombo-
sis and fibrinolysis regulation, and inflammation mediation. The normal endothelium may 
detect hemodynamics (e.g., pressure and friction forces) and hormonal changes (e.g., vaso-
active substances as well as mediators that occur in blood cells and platelets). As a conse-
quence, endothelial cells synthesize and release biologically active substances that maintain 
vascular homeostasis. Endothelial damage accompanied by endothelial dysfunction plays a 
crucial role and is associated with a prothrombotic state. Several reports associate nanoma-
terial exposure to endothelial damage [93–95] because blood is the main route for nanopar-
ticle transportation during distribution [96]. Some of the most important findings regarding 
nanoparticles and endothelial cell interaction are described below.
There are several reports in the literature regarding nanomaterials that affect cell viability and 
proliferation. Among them are gallium nitride nanoparticles (GaN NPs) [97], cerium dioxide 
nanoparticles (CeO
2
 NPs) [98], gold nanospheres [99, 100], silica NPs [101–103], CdTe [104], 
and silver nanoparticles [105] to quote some examples. Silver nanoparticles have received 
much attention as of late due to the biological effects they produce in endothelial cells, e.g., 
decreased cell viability, induced apoptosis, increased ROS production, increased produc-
tion of IL-6 and IL-8 interleukins, and increased expression of adhesion proteins, which can 
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 promote inflammation [106–108]. Sun et al. have shown that the interaction of silver nanopar-
ticles with the cell membrane of endothelial cells is the main factor behind endothelial dys-
function and may be associated with thromboembolic problems [109]. It has also been found 
that silicon nanoparticles induce oxidative stress, inflammation, alteration of the oxide nitric 
(NO) balance, and endothelial dysfunction via the activation of MAPK/Nrf2. They can also 
induce inflammation and cytotoxicity in endothelial cells through the activation of potassium 
channels [103]. Moreover, it has been suggested that nanoparticles can regulate the barrier 
function of tight junction (occludins, claudins, and ZO proteins) because they interact with 
key kinases, altering not only the oxidative status around the junction between endothelial 
cells but also altering the blood flow into the vessel [110]. These data indicate that nanopar-
ticle/endothelial cell interaction can modify the function of the blood vessel, whether in the 
site of injection at the moment of intravenous administration, during the distribution process, 
or when directed toward specific targets.
Nanomaterials are being used to direct and deliver drugs toward the endothelium and 
improve treatments for oncological, cardiovascular, pulmonary, neurologic, and ophthalmic 
diseases; they also have nanodiagnostic potential [111–121]. One of the problems in cancer is 
the formation of new blood vessels that irrigate the tumor (angiogenesis). Targeting nanopar-
ticles toward the tumor and allowing these to exert their harmful effects on the endothelial 
wall could reduce the size of the tumor due to lack of nutrients. Some of the nanomateri-
als used for this purpose are liposomes (Ala-Pro-Arg-Pro-Gly (APRPG) liposomes). These 
can successfully target tumor microvessels via functionalization with Ala-Pro-Arg-Pro-Gly 
(APRPG) peptide, which binds the blood vessels through the VEGF receptor-1 [122]. Another 
application involves the treatment of corneal endothelial dystrophy to improve and integrate 
cell therapy through superparamagnetic nanoparticles that facilitate the delivery of human 
corneal endothelial cells (HCECs) [123].
2. Conclusion
To summarize, the presence of nanomaterials within a dynamic environment such as the 
bloodstream can produce potentially harmful effects following interaction with several blood 
components. As reported in the literature, results have not been wholly encouraging because 
the said interaction can lead to different associated physiopathological processes linked to 
hemocompatibility. There is no doubt that nanomaterials might have theranostic potential for 
different clinical specialties and that their features improve upon traditional strategies: they 
are small and have physicochemical and optical properties that help direct molecules toward 
specific sites to control specific processes on a vascular level. However, the properties behind 
these advantages also create limitations, since most nanomaterials can cause important nano-
level interactions. The hemocompatibility of nanomaterials is essential when we consider 
that, regardless of the route of entry, the blood will transport them at any given time. Further 
in-depth studies are needed to understand, predict, and counteract the conduct of nanoma-
terials within the cellular and molecular microenvironments. The design of innovative strate-
gies leading to the development of more hemocompatible nanomaterials is also necessary.
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